| Drug General Information |
| Drug ID |
D0R6ZS
|
| Former ID |
DNC014279
|
| Drug Name |
N-(3-bromophenyl)-6-chloroquinazolin-4-amine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C14H9BrClN3
|
| Canonical SMILES |
C1=CC(=CC(=C1)Br)NC2=NC=NC3=C2C=C(C=C3)Cl
|
| InChI |
1S/C14H9BrClN3/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H,(H,17,18,19)
|
| InChIKey |
NBEFPXHBLZGXNK-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Metabotropic glutamate receptor 5 |
Target Info |
Inhibitor |
[1]
|
|---|
| Metabotropicglutamate receptor 1 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Long-term potentiation
|
|
Retrograde endocannabinoid signaling
|
|
Glutamatergic synapse
|
|
Huntington's diseasehsa04020:Calcium signaling pathway
|
|
FoxO signaling pathway
|
|
Long-term depression
|
|
Estrogen signaling pathway
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Metabotropic glutamate receptor group III pathway
|
|
Metabotropic glutamate receptor group I pathway
|
|
Endogenous cannabinoid signalingP00027:Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Endogenous cannabinoid signaling
|
|
Reactome
|
G alpha (q) signalling events
|
|
Class C/3 (Metabotropic glutamate/pheromone receptors)R-HSA-416476:G alpha (q) signalling events
|
|
Class C/3 (Metabotropic glutamate/pheromone receptors)
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
GPCRs, Class C Metabotropic glutamate, pheromone
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction
|
|
GPCR downstream signaling
|
|
GPCRs, Other
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. Epub 2009 Oct 9.Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. |
|---|
